Unicycive Therapeutics, Inc.
UNCY
$0.6379
$0.0081.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -100.00% | -100.00% |
| SG&A Expenses | 70.81% | 41.59% | 28.38% | 35.00% | 33.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.88% | 49.73% | 42.55% | 37.22% | 26.71% |
| Operating Income | -19.88% | -54.59% | -47.41% | -48.72% | -37.72% |
| Income Before Tax | 58.85% | -20.25% | 18.07% | 20.68% | -26.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.85% | -20.25% | 18.07% | 20.68% | -26.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.85% | -20.25% | 18.07% | 20.68% | -26.93% |
| EBIT | -19.88% | -54.59% | -47.41% | -48.72% | -37.72% |
| EBITDA | -19.88% | -54.56% | -47.38% | -48.70% | -37.69% |
| EPS Basic | 86.87% | 52.10% | 54.50% | 55.39% | 35.01% |
| Normalized Basic EPS | 101.24% | 62.29% | 64.00% | 63.91% | 37.07% |
| EPS Diluted | 64.58% | 37.88% | 41.34% | 43.77% | 34.83% |
| Normalized Diluted EPS | 88.39% | 52.38% | 54.84% | 55.87% | 37.07% |
| Average Basic Shares Outstanding | 197.01% | 173.07% | 151.52% | 131.52% | 94.76% |
| Average Diluted Shares Outstanding | 250.70% | 230.38% | 223.32% | 224.15% | 94.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |